Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Biodesix Inc (NASDAQ: BDSX) was $0.30 for the day, up 7.49% from the previous closing price of $0.28. In other words, the price has increased by $7.49 from its previous closing price. On the day, 2.41 million shares were traded.
Ratios:
Our analysis of BDSX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.14 and its Current Ratio is at 2.22. In the meantime, Its Debt-to-Equity ratio is 5.63 whereas as Long-Term Debt/Eq ratio is at 5.53.
On July 26, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $3.Craig Hallum initiated its Buy rating on July 26, 2024, with a $3 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 16 ’25 when SCHULER JACK W bought 4,000,000 shares for $0.27 per share. The transaction valued at 1,070,000 led to the insider holds 20,194,935 shares of the business.
SCHULER JACK W bought 723,239 shares of BDSX for $246,624 on May 19 ’25. The Director now owns 20,918,174 shares after completing the transaction at $0.34 per share. On May 12 ’25, another insider, Vazquez Chris, who serves as the Chief Accounting Officer of the company, sold 112 shares for $0.36 each. As a result, the insider received 40 and left with 18,113 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.60 while its Price-to-Book (P/B) ratio in mrq is 4.01.
Stock Price History:
Over the past 52 weeks, BDSX has reached a high of $2.04, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is -33.51%, while the 200-Day Moving Average is calculated to be -73.00%.
Shares Statistics:
A total of 146.44M shares are outstanding, with a floating share count of 69.40M. Insiders hold about 52.65% of the company’s shares, while institutions hold 36.42% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $19.1M to a low estimate of $17.9M. As of the current estimate, Biodesix Inc’s year-ago sales were $17.93MFor the next quarter, 6 analysts are estimating revenue of $20.82M. There is a high estimate of $21.6M for the next quarter, whereas the lowest estimate is $19.5M.
A total of 6 analysts have provided revenue estimates for BDSX’s current fiscal year. The highest revenue estimate was $83.9M, while the lowest revenue estimate was $78.4M, resulting in an average revenue estimate of $82.02M. In the same quarter a year ago, actual revenue was $71.32MBased on 6 analysts’ estimates, the company’s revenue will be $106.06M in the next fiscal year. The high estimate is $117.4M and the low estimate is $100.4M.
